2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Cardiovascular disease
Chronic kidney disease
Glucose-lowering therapy
Guidelines
Heart failure
Hypoglycaemia
Patient-centred care
Type 2 diabetes mellitus
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
20
12
2019
medline:
2
2
2021
entrez:
20
12
2019
Statut:
ppublish
Résumé
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA
Identifiants
pubmed: 31853556
doi: 10.1007/s00125-019-05039-w
pii: 10.1007/s00125-019-05039-w
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-228Commentaires et corrections
Type : ErratumIn
Références
Lancet Diabetes Endocrinol. 2019 May;7(5):356-367
pubmed: 30833170
N Engl J Med. 2019 Aug 29;381(9):841-851
pubmed: 31185157
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Lancet Diabetes Endocrinol. 2018 May;6(5):370-381
pubmed: 29483060
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Circulation. 2019 May 28;139(22):2528-2536
pubmed: 30882238
Lancet. 2019 Oct 26;394(10208):1519-1529
pubmed: 31542292
Circulation. 2018 Oct 23;138(17):1904-1907
pubmed: 30354665
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016
pubmed: 27651331
Circulation. 2019 Apr 23;139(17):2022-2031
pubmed: 30786725
Circulation. 2019 Aug 27;140(9):739-750
pubmed: 31291786
Circulation. 2019 May 28;139(22):2591-2593
pubmed: 30882240
JAMA. 2019 Jan 1;321(1):69-79
pubmed: 30418475
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
Diabetes Obes Metab. 2019 Nov;21(11):2576-2580
pubmed: 31373167
JAMA. 2019 Sep 19;:
pubmed: 31536101